Next Generation Immunotherapies Global Market Report 2025

The next generation immunotherapies market size has grown rapidly in recent years. It will grow from $133.81 billion in 2024 to $150.54 billion in 2025 at a compound annual growth rate (CAGR) of 12.5%. The growth during the historic period can be attributed to the increasing prevalence of oncology, higher investments in research and development, rising government initiatives, increased healthcare expenditures, and the expanding range of indications for immunotherapies.

The next generation immunotherapies market size is expected to see rapid growth in the next few years. It will grow to $238.04 billion in 2029 at a compound annual growth rate (CAGR) of 12.1%. The growth during the forecast period can be attributed to the rising prevalence of cancer, increasing healthcare expenditure, growing adoption of chimeric antigen receptor (CAR) T-cell therapy, a higher burden of chronic diseases, and expanding research in next-generation drugs. Key trends in the forecast period include a shift toward combination therapies, technological advancements, innovations in therapeutic approaches, progress in personalized medicine, and enhanced regulatory support.

The growing prevalence of cancer is expected to drive the expansion of the next-generation immunotherapies market. Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells within the body. Several factors contribute to the increasing incidence of cancer, including aging populations, lifestyle changes, environmental exposures, and advancements in detection methods. Next-generation immunotherapies offer advanced, targeted treatments that enhance the body's immune response to cancer, providing improved effectiveness, durability, and personalization. For example, in May 2024, the National Cancer Institute (NCI), a US-based government agency, reported that nearly 20 million new cancer cases and 9.7 million cancer-related deaths occurred globally in 2022. Projections for 2040 estimate 29.9 million new cases and 15.3 million cancer-related deaths. Consequently, the rising prevalence of cancer is fueling the growth of the next-generation immunotherapies market.

Leading companies in the next-generation immunotherapies market are focusing on the development of innovative treatments, such as CAR T-cell therapy, to address cancers, autoimmune diseases, and infectious diseases. CAR T-cell therapy is an advanced immunotherapy technique in which a patient's T cells (a type of immune cell) are genetically engineered to express chimeric antigen receptors (CARs). For instance, in January 2025, Immuneel Therapeutics Private Limited, an India-based cell and gene therapy startup, introduced Qartemi, India's first CAR T-cell therapy. This treatment targets adult B-cell non-Hodgkin lymphoma by genetically modifying a patient’s immune cells to recognize and eliminate cancer cells, offering a highly effective and personalized approach. It presents new hope for patients who have not responded to conventional treatments, with the added benefit of being more cost-effective than similar international options.

In September 2023, Coherus BioSciences Inc., a US-based biopharmaceutical company, acquired Surface Oncology Inc. for an undisclosed amount. This acquisition is part of Coherus BioSciences’ strategy to expand its immuno-oncology portfolio by developing novel therapies that target the tumor microenvironment to enhance cancer treatment. Surface Oncology Inc., a US-based immuno-oncology company, specializes in next-generation immunotherapies designed to modify the tumor microenvironment for improved treatment outcomes.

Major players in the next generation immunotherapies market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Incyte Corporation, BioNTech SE, Xencor Inc., Fate Therapeutics Inc., Immatics N.V., Atara Biotherapeutics Inc., Menarini Group, Alpine Immune Sciences Inc., Mereo Biopharma Group plc, Immunomic Therapeutics Inc., Indaptus Therapeutics Inc.

North America was the largest region in the next-generation immunotherapies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the Next Generation Immunotherapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Next-generation immunotherapies are advanced treatments designed to enhance the body's immune system to combat diseases, particularly cancer, with greater precision, efficacy, and safety. These therapies surpass traditional immune-based treatments by utilizing cutting-edge technologies to overcome previous limitations, minimize side effects, and provide long-lasting immune responses.

The primary drug classes in next-generation immunotherapies include monoclonal antibodies, antibody-drug conjugates (ADCs), angiotensin-converting enzyme (ACE) inhibitors, and immune checkpoint inhibitors. Monoclonal antibodies are lab-engineered proteins that precisely target specific antigens, boosting immune response and treatment effectiveness. These drugs are administered through various routes, such as intravenous, parenteral, intratumoral, subcutaneous, and oral. They are distributed through multiple channels, including hospital pharmacies, clinical pharmacies, and other distribution networks.

The next-generation immunotherapies market research report is one of a series of new reports that provides next-generation immunotherapies market statistics, including the next-generation immunotherapies industry global market size, regional shares, competitors with the next-generation immunotherapies market share, detailed next-generation immunotherapies market segments, market trends, and opportunities, and any further data you may need to thrive in the next-generation immunotherapies industry. This next-generation immunotherapies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The next-generation immunotherapies market consists of revenues earned by entities providing services such as cell therapy manufacturing services, gene editing and engineering services, consulting services, diagnostic services, and distribution and logistics. The market value includes the value of related goods sold by the service provider or included within the service offering. The next-generation immunotherapies market also includes sales of CAR-T cell therapies, natural killer (NK) cell therapies, combination therapies, and checkpoint inhibitors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.